newsfilter
← Latest News
GlobeNewswire·

Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) (the "Company", "Opus Genetics" or "Opus"), a clinical-stage biopharmaceutical company